CGRP, calcitonin gene-related peptide, is the key molecule driving migraine. Learn how it works and why anti-CGRP treatments are changing prevention.
CGRP, or calcitonin gene-related peptide, is a neuropeptide released by the trigeminal nerve during migraine attacks that widens blood vessels, drives inflammation, and amplifies pain signals, which makes it the main molecular target for modern migraine prevention. For decades, migraine was instead treated as a generic pain problem, with treatments borrowed from other conditions. That changed when researchers identified CGRP as a central driver of attacks. Understanding what CGRP does, and how newer medications target it, is one of the most useful things a migraine patient can know.
Calcitonin gene-related peptide is a small protein, technically a neuropeptide, produced throughout the nervous system. Under normal circumstances, CGRP plays a useful role: it helps regulate blood vessel tone, participates in transmitting sensory signals, and contributes to wound healing and cardiovascular function. It is particularly abundant in the trigeminal nerve, the large sensory nerve that supplies the face, scalp, and structures inside the skull.
In healthy people, CGRP levels rise and fall as part of normal physiology. The problem in migraine is not that CGRP exists. During an attack, it shows up in the wrong amounts, in the wrong places, at the wrong time.
When a migraine begins, the trigeminal nerve system activates. Nerve endings release CGRP in large quantities around the blood vessels of the meninges, the protective membranes surrounding the brain. This surge of CGRP causes blood vessels to dilate and become inflamed. It also amplifies pain signals and contributes to the hypersensitivity that makes light, sound, and movement unbearable during a migraine.
Studies measuring CGRP in blood and saliva have consistently shown elevated levels during attacks, and the levels drop when attacks resolve, sometimes naturally, sometimes in response to triptans. This tight correlation between CGRP release and migraine activity is what made it such a compelling target for drug development.
CGRP also appears to lower the threshold at which the trigeminal system fires. This may explain why, for people with frequent or chronic migraine, the nervous system seems to be in a near-constant state of readiness to attack. Keeping CGRP activity suppressed, rather than treating it only after an attack starts, became the rationale for a new class of preventive therapies.
The biggest shift in migraine prevention in a generation came from anti-CGRP monoclonal antibodies. These are large-molecule biologic medications, engineered proteins designed to neutralize a specific target with high precision. There are currently four approved in the United States, and they fall into two camps.
Three of them, fremanezumab, galcanezumab, and eptinezumab, target the CGRP molecule itself, binding to it and preventing it from attaching to its receptor. The fourth, erenumab, takes a different approach: instead of blocking CGRP, it blocks the CGRP receptor, so the molecule has nowhere to land even if it is released.
Both strategies interrupt the same signaling cascade. The practical result is that less CGRP activity reaches the trigeminal system, and the nervous system becomes less primed to generate attacks.
Three of these medications are given by injection, either monthly or quarterly depending on the specific drug and dose. Eptinezumab is administered intravenously, typically every three months in a clinical setting. The injections are generally well tolerated; the most common side effects are injection-site reactions and, for some patients, constipation.
For people who qualify, anti-CGRP monoclonal antibodies have shown meaningful reductions in monthly migraine days in clinical trials: not elimination, but a genuine reduction that translates to real improvement in quality of life for many patients.
Monoclonal antibodies require injections and are large molecules that do not cross the blood-brain barrier. Gepants are a different class of CGRP-targeting drugs: small molecules taken orally that block the CGRP receptor.
Rimegepant and atogepant are currently approved for migraine prevention. Rimegepant is also approved for acute treatment, making it one of the few molecules with evidence supporting both uses. Atogepant is taken daily as a preventive.
Gepants are particularly relevant for patients who cannot tolerate injections, who have cardiovascular contraindications to triptans (since gepants do not cause vasoconstriction the way triptans do), or who prefer an oral daily medication. They are also being used in combination with monoclonal antibodies in some clinical scenarios, though that is a decision for a treating neurologist to make based on individual circumstances.
This article is for educational purposes only and does not constitute medical advice. If you are considering a CGRP-targeted treatment, speak with a neurologist or headache specialist who can evaluate your full history.
Anti-CGRP preventives are typically considered for people with a meaningful migraine burden who have not gotten adequate relief from older options. Clinical guidelines generally point toward patients with episodic migraine who experience four or more migraine days per month, and patients with chronic migraine, defined as 15 or more headache days per month, at least eight of which have migrainous features.
"Adequate response" is a phrase that comes up often in headache medicine, and it is worth understanding what it means in practice. Most headache specialists consider a 50% or greater reduction in monthly migraine days to be a meaningful response to a preventive. Someone who was having 12 migraine days per month and drops to five or six on a new treatment is generally considered a responder. Someone who sees little or no change after a sufficient trial period, typically three to six months, may be considered a non-responder and be evaluated for a different approach.
It is also worth knowing that anti-CGRP therapies are not universally covered by insurance as a first-line option. Many insurers require documented failure of one or more older preventives, such as beta-blockers, antidepressants, or anticonvulsants, before approving a newer CGRP-targeted medication. Navigating prior authorization is a real part of the process for many patients.
Here is where the clinical language meets everyday life: none of the conversations about "adequate response" or "50% reduction" are possible without accurate data. A neurologist cannot evaluate whether a treatment is working if the patient has only a rough sense of how often they had headaches over the past three months.
Consistent daily tracking, even a simple log of whether you had a migraine, its severity, and any medications you took, gives both you and your doctor the clearest possible picture of what your nervous system is doing. It reveals patterns: whether your attacks cluster around your cycle, your sleep, or particular triggers. It documents your baseline before starting a new treatment, so you have something concrete to compare against six months in.
CGRP research has transformed what is possible for migraine patients. The treatments work differently for different people, and finding the right fit takes time and accurate information. Tracking is not just a habit: it is the data layer underneath every decision you and your neurologist will make together.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
CGRP stands for calcitonin gene-related peptide, a neuropeptide released during migraine attacks that dilates blood vessels and amplifies pain signals.
Using pain relief too often can make migraines worse, not better. Here's what medication overuse headache is, which drugs carry the highest risk, and how to break the cycle.
Many migraineurs swear by weather triggers, but the science is more nuanced. Here's what research shows about barometric pressure and migraine, and what to do about it.
Comparing CGRP monoclonal antibodies vs gepants? Learn how each class works, how they differ in use and timing, and what questions to bring to your clinician.
